Adaptations of NMDA and dopamine D2, but not of muscarinic receptors following 14 days administration of uncompetitive NMDA receptor antagonists

Journal of Neural Transmission

Volumn 106, Issue 5-6, 1999, Pages 409-421

  Hesselink, M B ^a,b   De Boer, A G ^b   Breimer, D D ^b   Danysz, W ^a  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

(+)MK 801; Amantadine; Dopamine D2 receptor; Memantine; Muscarinic receptor; NMDA receptor; Receptor autoradiography

Indexed keywords

AMANTADINE; DIZOCILPINE; DOPAMINE 2 RECEPTOR; MEMANTINE; MUSCARINIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DENTATE GYRUS; FRONTAL CORTEX; HIPPOCAMPUS; MALE; MINIPUMP; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; SUBCUTANEOUS DRUG ADMINISTRATION; TIME;

AMANTADINE; ANIMALS; BRAIN; CAUDATE NUCLEUS; DENTATE GYRUS; DIZOCILPINE MALEATE; ENTORHINAL CORTEX; FRONTAL LOBE; HIPPOCAMPUS; INFUSIONS, PARENTERAL; KINETICS; MALE; MEMANTINE; NUCLEUS ACCUMBENS; ORGAN SPECIFICITY; RACLOPRIDE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RECEPTORS, MUSCARINIC; RECEPTORS, N-METHYL-D-ASPARTATE; SALICYLAMIDES; TIME FACTORS;

EID: 0033055356     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020050168     Document Type: Article

References (37)

1. Anis NA, Berry SC, Burton NR, Lodge D (1983) The dissociative aneasthetics ketamine and phencyclidine, selectively inhibit excitation of central mammalian neurons by N-methylaspartate. Br J Pharmacol 79: 565-575
2. Beart PM, Lodge D (1990) Chronic administration of MK-801 and the NMDA receptor: further evidence for reduced sensitivity of the primary acceptor site from studies with the cortical wedge preparation. J Pharm Pharmacol 42: 354-355
3. Bresink I, Danysz W, Parsons CG, Tiedtke P, Mutschler E (1995) Chronic treatment with the uncompetitive NMDA receptor antagonist memantine influences the polyamine and glycine binding sites of the NMDA receptor complex in aged rats. J Neural Transm [PD-Sect] 10: 11-26
4. Collingridge GL, Singer W (1990) Excitatory amino acid receptors and synaptic plasticity. Trends Pharmacol Sci 11: 290-296
5. Danysz W, Parsons CG, Bresink I, Quack G (1995) Glutamate in CNS disorders - a revived target for drug development. Drug News Perspect 8: 261-277
6. Danysz W, Parsons CG, Kornhuber J, Schmidt WJ, Quack G (1997) Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - preclinical studies. Neurosci Biobehav Rev 21: 455-468
7. Ditzler K (1991) Efficacy and tolerability of memantine in patients with dementia syndrome. Arzneimittelforschung 8: 773-780
8. Hesselink MB, Smolders H, Danysz W, Lorenz B, Eilbacher B, de Boer AG, Breimer DD (1997) Pharmacokinetic characterization of two distinct classes of NMDA receptor antagonists using brain microdialysis. Soc Neurosci Abstr 23: 921
9. Hesselink MB, Smolders H, de Boer AG, Breimer DD, Danysz W (1999) Modifications in the behavioral profile of uncompetitive NMDA receptor antagonists, memantine, amantadine, and (+)MK-801 after chronic administration. Behav Pharmacol 10 (in press)
10. Honey CR, Miljkovic Z, MacDonald JF (1985) Ketamine and pheneyclidine cause a voltage-dependent block of responses to I-aspartic acid. Neurosci Lett 61: 135-139
11. Kakkar R, Raju RVS, Rajput AH, Sharma RK (1997) Amantadine: an antiparkinsonian agent inhibits bovine brain 60kDa calmodulin-dependent cyclic nucleotide phosphodiesterase isozyme. Brain Res 749: 290-294
12. Kalivas PW (1995) Interactions between dopamine and excitatory amino acids in behavioral sensitization to psychostimulants. Drug Alcohol Dep 37: 95-100
13. Kornhuber J, Quack G (1995) Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neurosci Lett 195: 137-139
14. Kornhuber J, Bormann J, Hubers M, Rusche K, Riederer P (1991) Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel -a human postmortem brain study. Eur J Pharmacol 206: 297-300
15. Kornhuber J, Weller M, Schoppmeyer K, Riederer P (1994) Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm [Suppl] 43: 91-104
16. Kurumaji A, Ikeda M, Dewar D, McCormack A, McCulloch J (1991) Effects of chronic administration of MK-801 upon local cerebral glucose utilisation and ligand binding to the NMDA receptor complex. Brain Res 563: 57-65
17. Lannes B, Bernard V, Bloch B, Micheletti G (1995) Chronic treatment with dizocilpine maleate increases the number of striatal neurons expressing the d-2 receptor gene. Neuroscience 65: 431-438
18. Leppik IE, Marienau K, Graves NM, Rask CA (1988) MK-801 for epilepsy: a pilot study. Neurology 38 [Suppl 1]: 405
19. 3H]SCH23390. Neuroscience 40: 657-671
20. Löscher W (1993) Basic aspects of epilepsy. Curr Opin Neurol Neurosurg 6: 223-232
21. 3H]D-AP5, suggesting down-regulation of the cortical N-methyl-D-aspartate receptors. Neuroscience 30: 87-94
22. Micheletti G, Lannes B, Haby C, Borrelli E, Kempf E, Warter JM, Zwiller J (1992) Chronic administration of NMDA antagonists induces D2 receptor synthesis in rat striatum. Mol Brain Res 14: 363-368
23. Misztal M, Frankiewicz T, Parsons CG, Danysz W (1996) Learning deficits induced by chronic intraventricular infusion of quinolinic acid - protection by MK-801 and memantine. Eur J Pharmacol 296: 1-8
24. Morita T, Hitomi S, Saito S, Fujita T, Uchihashi Y, Kuribara H (1995) Repeated ketamine administration produces up-regulation of muscarinic acetylcholine receptors in the forebrain, and reduces behavioral sensitivity to scopolamine in mice. Psychopharmacology 117:396-402
25. Murase K, Nabeshima T, Kameyama T, Sasa M, Takaori S, Ujihara H, Ishihara K, Yamada J, Serikawa T (1991) Characteristics of muscarinic cholinergic, gamma-aminobutyric acid(A) and phencyclidine receptors in spontaneously epileptic rats; in vitro quantitative autoradiographic analysis. Neurosci Lett 131: 1-4
26. Parsons CG, Gruner R, Rozental J, Millar J, Lodge D (1993) Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology 32: 1337-1350
27. Qin ZH, Zhou LW, Weiss B (1994) D-2 dopamine receptor messenger RNA is altered to a greater extent by blockade of glutamate receptors than by blockade of dopamine receptors. Neuroscience 60: 97-114
28. 3H]MK-801 binding sites determined by quantitative autoradiography in rat brain. Neuroscience 40: 533-543
29. Schmidt WJ (1995) Balance of transmitter activities in the basal ganglia loops. J Neural Transm [Suppl] 46: 67-76
30. Schwab RS, England AC, Poskranzer DC, Young RR (1969) Amantadine in the treatment of Parkinson's disease. JAMA 208: 1168-1170
31. Schwartz PH, Wasterlain CG (1993) Determination of serum and brain concentrations of neuroprotective and non-neuroprotective doses of MK-801. J Neurol Sci 115: 26-31
32. Stephens DN (1995) A glutamatergic hypothesis of drug dependence: extrapolations from benzodiazepine receptor ligands. Behav Pharmacol 6: 425-446
33. Trujillo KA, Akil H (1991) Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 251: 85-87
34. Vezzani A, Serafini R, Stasi MA, Caccia S, Conti I, Tridico RV, Samanin R (1989) Kinetics of MK-801 and its effect on quinolinic acid-induced seizures and neurotoxicity in rats. J Pharmacol Exp Ther 249: 278-283
35. Wenk GL, Zajaczkowski W, Danysz W (1997) Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B. Behav Brain Res 83: 129-133
36. Willis CL, Brazell C, Foster AC (1991) Plasma and CSF levels of dizocilpine (MK-801) required for neuroprotection in the quinolinate-injected rat striatum. Eur J Pharmacol 196: 285-290
37. Wolf ME (1998) The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog Neurobiol 54: 679-720